Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00195026 · ClinicalTrials.gov registry record

Infrared Imaging (Breast Scan IR) for Early Breast Cancer Detection

A clinical trial of Breast Cancer, sponsored by Weill Medical College of Cornell University.

Completed
Registry status
200
Enrollment target
1
Study location

NCT00195026 is a study of Breast Cancer that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 200 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00195026, a study of Breast Cancer, has completed, sponsored by Weill Medical College of Cornell University.

COMPLETED
Registry status
200 participants
Enrollment target
1
Study location

Study Summary

This protocol will evaluate a new non-invasive infrared imaging system as an adjunctive tool for breast cancer detection that has been approved by the FDA. The technology and device have been developed by Infrared Sciences Corp. and has undergone more than 3 years of testing prior. The subject device's utility will be investigated with regard to its sensitivity toward breast cancer, however it records temperature data and other physiological parameters of the breast, and compares them to a database of patients with known breast health.

Conditions Studied

Interventions

  • DEVICE Infrared Breast Scan

Study Locations (1)

New York

  • Weill Cornell Breast Center - New York

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2005-03

What the Registry Record Tells You About NCT00195026

The ClinicalTrials.gov registry entry for NCT00195026 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Infrared Breast Scan is the first listed.

NCT00195026 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00195026 about?

NCT00195026 is a clinical study titled "Infrared Imaging (Breast Scan IR) for Early Breast Cancer Detection". This protocol will evaluate a new non-invasive infrared imaging system as an adjunctive tool for breast cancer detection that has been approved by the FDA. The technology and device have been developed by Infrared Sciences Corp. and has undergone more than 3 years of testing prior. The subject devic...

What is the current status of trial NCT00195026?

This trial is currently completed. The enrollment target is 200 participants. The study started on 2005-03.

What conditions does trial NCT00195026 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00195026?

The interventions under investigation include: Infrared Breast Scan (DEVICE).

Who is sponsoring clinical trial NCT00195026?

This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00195026 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.